Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 10, 2009

DrStockPick.com Stock Report!

PWRM, TEVA

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

For Immediate Release

Chicago, IL – November 5, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baker Hughes Inc. (BHI), BJ Services (BJS), Teva Pharmaceutical Industries Ltd. (TEVA), Mylan (MYL) and Comcast Corp. (CMCSA).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s AnalystBlog:

Baker Hughes Misses Estimates

Baker Hughes Inc. (BHI) reported its third quarter results of 26 cents per share, well below the Zacks Consensus Estimate of 36 cents and year-earlier quarter earnings of $1.39. Before adjusting one-time items, earnings were 18 cents per share.

Though the company’s

...

DrStockPick.com Stock Report!

Monday August 3, 2009

**************************************************************

CTI Industries Corporation (NASDAQ: CTIB), today announced that it will host a conference call and live webcast to discuss fiscal 2009 second quarter earnings and 2009 year-to-date financial results. The conference call and webcast will take place on Wednesday, August 12, 2009 at 10:00 a.m. Central Daylight Time (11:00 a.m. Eastern Daylight Time).

Hagens Berman Sobol Shapiro is investigating reports of possible securities law violations by Genzyme Corporation (Nasdaq:GENZ), a biotechnology company, following reports that the company may have delayed news concerning manufacturing problems and plant inspections by the Food and Drug Administration (FDA).

RiT Technologies (NASDAQ: RITT) today announced that its previously announced one-for-eight

...

On July 28, 2009, Teva Pharmaceutical Industries Ltd. (TEVA) reported financial results for the second quarter ended June 30, 2009. Net sales increased 20% y-o-y to $3.4 billion in the reported quarter, missing the consensus estimate by a small margin. The strengthening U.S. dollar adversely impacted net sales by $256 million or 9%. Non-GAAP net income increased 25% to $742 million. Non-GAAP EPS of $0.83 (up 15% y-o-y) exceeded our and consensus estimate of $0.81 and $0.80, respectively. Strong sales, improved gross margins (due to better product mix) and lower-than-expected R&D expenses helped drive earnings in the reported quarter. GAAP net income declined 2.3% to $521 million or $0.58 per share. Revenue performance across key business segments was mixed. While total pharmaceutical sales increased 22% y-o-y to about $3.3 billion in the reported quarter, total API business sales declined 13% y-o-y to $135 million. The ...

MFS New Endeavor A (MECAX) was incepted in September 2000. The investment seeks capital appreciation.

The fund focuses on small capitalization stocks but is designed to be diversified by sector with the flexibility to invest across industries and styles. It may enter into short sales and invest in derivatives.

Camille H. Lee has managed the fund since December 2005. Lee has 22 years of industry experience. The fund has an expense ratio of 1.83%.

MFS Emerging Markets Equity A (MEMAX) seeks capital appreciation. The fund normally invests at least 80% of net assets in equity securities of issuers that are tied economically to emerging-market countries.

This regionally focused fund has the flexibility to invest across sectors, countries, and market capitalizations. As of February 2009, its portfolio turnover was 94%.

Brazilian Petroleum Corp. (PBR), Teva Pharmaceutical Industries Ltd. (TEVA) and

...

 

For Immediate Release

Chicago, IL - May 4, 2009 - Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list includes Walt Disney Company (DIS), Activision Blizzard (ATVI), California Pizza Kitchen (CPKI), Goldcorp (GG) and Teva Pharmaceutical Industries Ltd. (TEVA). To see more earnings analysis, visit http://at.zacks.com/?id=3207.

Every day, Zacks.com makes 4 stock picks available, free of charge. To see them, go to http://at.zacks.com/?id=3567.

The Week's Events

Another busy week.

Results from the bank stress tests are penciled for Thursday. The release date was pushed back after several banks objected to the initial findings. It's not just the results that will matter, but also how much validity the financial markets give them.

On the earnings front, about 850 companies are confirmed to report, including 86 members of the S&P 500. Dow components Kraft

...

Teva Pharmaceutical Industries Ltd. (TEVA) fell almost 2% in the early session amid a broader market slump and was approaching support at $43.86. Teva is a Zacks#1 Rank ("Strong Buy") stock that has topped the average forecast in each of the last 4 quarters with an average surprise of 2.90% or 2 cents per share.

Zacks Investment Research

Medicis Pharmaceutical Corp. (MRX) slumped the most in 12 years on Wednesday after the U.S. Food and Drug Administration rejected the company's appeal for banning generic versions of its acne drug Solodyn from entering the market before the patent expired.

Mylan Inc. (MYL), Barr Laboratories Inc. and Novartis AG (NVS) unit Sandoz Inc. have submitted abbreviated new drug applications (ANDAs) for Solodyn. Israel-based Teva Pharmaceutical Industries Ltd. (TEVA) has already received a nod from federal health regulators to market its generic version of the oral antibiotic and began shipment of the product.

Medicis filed its petition for a 30-month stay on ANDAs of Solodyn, after suing all the generic makers. Solodyn, which is scheduled to lose patent protection in 2018, contributes nearly 50% of the Scottsdale, Arizona-based company's total revenue.

Shares of the company are down more than 11% today.

"MRX" Free Stock ...